Recent Research Funding

Michael E. Duffey, PhD.

For decades, National Institutes of Health funding has supported Michael E. Duffey, PhD, whose work has been published in top journals such as Nature.

We receive funding from a variety of sources that recognize the value of our high-impact research.

  • Investigating the Action and Physiological Role of Slc4a11 in the Cornea. Michael Duffey (Co-Investigator). NIH National Eye Institute. $1,972,804. 2/1/2018-9/1/2028.
  • Investigating the Action and Physiological Role of Slc4a11 in the Cornea. Mark Parker (Principal Investigator). NIH National Eye Institute. 1/1/2018-9/1/2028.
  • Preventing and Reversing Interstitial Fibrosis in HFpEF. Brian Weil (Co-Investigator). Veteran's Affairs Merit Review Award. $709,984. 10/1/2020-9/1/2028.
  • A Multifactorial Mechanism for Alzheimer’s Disease. Zhen Yan (Principal Investigator). VA. $1,115,372. 10/1/2024-9/1/2028.
  • Therapeutic targeting of master regulators in non-canonical AR driven advanced lethal prostate cancers. Wilma Hofmann (Co-Investigator). NIH/NCI. 8/1/2023-7/1/2028.
  • Novel Inhibitors of Lysine Methyltransferases G9a and GLP for the Treatment of Alzheimer's Disease. Zhen Yan (Co-Investigator). NIA/NIH. $3,309,300. 9/1/2023-6/1/2028.
  • Epigenetics-Based Autism Treatment with Animal Models and Human Stem Cells. Zhen Yan (Principal Investigator). NINDS/NIH. $3,088,565. 2/1/2023-1/1/2028.
  • Epigenetics-Based Autism Treatment with Animal Models and Human Stem Cells. Jian Feng (Principal Investigator). NINDS. $1,544,283. 2/1/2023-1/1/2028.
  • Transcriptomic and Circuitry Aberrations in Alzheimer’s Disease. Zhen Yan (Principal Investigator). NIA/NIH. $3,710,395. 12/1/2022-11/1/2027.
  • Transcriptomic and Circuitry Aberrations in Alzheimer’s Disease. Jian Feng (Principal Investigator). NIA. $1,855,198. 12/1/2022-11/1/2027.
  • Development and plasticity of stimulus processing in the visual cortex. Sandra Kuhlman (Principal Investigator). National Eye Institute. 9/1/2023-6/1/2027.
  • Repetitive Stretch-Induced Myocardial Stiffening in Chronic Coronary Artery Disease. Brian Weil (Principal Investigator). U.S. Department of Veterans Affairs. $1,037,189. 4/1/2023-3/1/2027.
  • Immunomodulatory Therapy After Resuscitation From Cardiac Arrest. Brian Weil (Principal Investigator). National Institutes of Health (NHLBI). $2,278,145. 1/1/2022-12/1/2026.
  • Role of parafascicular thalamus in motor behavior relevant to Parkinson’s disease. Dheeraj Roy (Principal Investigator). NINDS. $660,000. 1/1/2024-12/1/2026.
  • Modeling and testing functional interactions among corneal endothelial acid-base transporters. Mark Parker (Co-Principal Investigator). NIH National Eye Institute. 5/1/2024-4/1/2026.
  • Role of epicardial adiposity as a local mediator of VT/VF dynamics in donor hearts. Kedar Aras (Principal Investigator). NIH/NHLBI. $750,000. 3/1/2023-2/1/2026.
  • Synaptic and Genetic Mechanisms of Sex-Specific Effects of Stress. Zhen Yan (Principal Investigator). NIMH/NIH. $2,621,841. 4/1/2021-1/1/2026.
  • Predoctoral Fellowship for Tyler Rolland: "Mechanisms of Mitochondrial DNA-mediated Immune Activation in Post-Cardiac Arrest Syndrome". Brian Weil (Co-Principal Investigator). American Heart Association. 1/1/2024-12/1/2025.
  • Investigating the role of NBCe1-B in renal and cardiac acid-base handling. Mark Parker (Consultant). NIH National Institute of Diabetes and Digestive and Kidney Diseases. 7/1/2020-7/1/2025.
  • Molecular Segregation of Parkinson’s Disease by Patient-derived Neurons. Jian Feng (Principal Investigator). NINDS/NIH. $2,244,925. 6/1/2020-5/1/2025.